Search research articles
Contact Us
Filters
Showing results (111-120 of 130) with videos related to
Page
of 13
Sort By:
Cancers
|
February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2022
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
Georg C Lodde, Philipp Jansen, Inga Möller, et al.
Cancers
|
February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
Michael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Georg C Lodde, Fang Zhao, Rudolf Herbst, et al.
The Lancet. Haematology
|
February 6, 2026
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Rudolf Stadler, Pietro Quaglino, F J Sherida H Woei-A-Jin, et al.
Journal for Immunotherapy of Cancer
|
February 4, 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Thomas Eigentler, Ioannis Thomas, Igor Samoylenko, et al.
Journal for Immunotherapy of Cancer
|
June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
Cindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
Anna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Journal for Immunotherapy of Cancer
|
May 14, 2021
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Nikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
Inês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 130) with videos related to
Sort By:
Page
of 13
Cancers
|
February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
Elias A T Koch, Anne Petzold, Anja Wessely, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2022
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
Georg C Lodde, Philipp Jansen, Inga Möller, et al.
Cancers
|
February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
Michael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Georg C Lodde, Fang Zhao, Rudolf Herbst, et al.
The Lancet. Haematology
|
February 6, 2026
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Rudolf Stadler, Pietro Quaglino, F J Sherida H Woei-A-Jin, et al.
Journal for Immunotherapy of Cancer
|
February 4, 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Thomas Eigentler, Ioannis Thomas, Igor Samoylenko, et al.
Journal for Immunotherapy of Cancer
|
June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
Cindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
Anna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Journal for Immunotherapy of Cancer
|
May 14, 2021
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Nikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
Inês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
Page
of 13